Jaknat 10 Tablet contains Tofacitinib 10 mg, a Janus kinase (JAK) inhibitor used primarily in the treatment of autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib works by selectively inhibiting the JAK enzymes, which play a crucial role in the signaling pathways that regulate immune responses and inflammation. By modulating these pathways, Jaknat 10 helps reduce the symptoms of inflammation, joint damage, and tissue destruction associated with these chronic conditions. It is typically prescribed for patients who have had an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (DMARDs). The medication is administered orally, with dosage and duration tailored to the individual patient’s condition and response to therapy. Common side effects may include upper respiratory tract infections, headache, diarrhea, and increased risk of serious infections due to immunosuppression. Regular monitoring of blood counts, liver function, and lipid profiles is recommended during treatment. Jaknat 10 should be used under strict medical supervision, with caution in patients with a history of infections, malignancies, or liver impairment. It is contraindicated in patients with active infections and should not be combined with other potent immunosuppressants.